Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
Observational · No treatment assigned · Sites not listed yet · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Chronic Disease, Immunocompromised and HIV Infection. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Adults aged ≥18 years
- Presence of at least one chronic or immunocompromising condition eligible for vaccination according to national guidelines
- Written informed consent provided
There are also 2 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 1500 participants are expected to take part.
- Start date: 2026-02 (planned).
- Main results expected around 2027-02 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- Vaccination Offer Rate (12 months)
In the researchers’ words
AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting. The study targets adult and elderly patients with chronic diseases or immunocompromising conditions who are eligible for vaccination according to national immunization guidelines.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Chronic Disease; Immunocompromised; HIV Infection; Chronic Kidney Disease; Solid Organ Transplantation; Hematopoietic Stem Cell Transplantation; Cancer; Autoimmune Diseases; Inflammatory Bowel Disease; Asplenia; Frailty |
| Lead sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Collaborators | Pfizer |
| Enrollment | 1500 (estimated) |
| Start date | 2026-02 |
| Primary completion (est.) | 2027-02 |
| First posted | 2026-02-05 |
| Last updated | 2026-02-05 |
| Official title | Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients: A Scalable and Sustainable Model |
| ClinicalTrials.gov ID | NCT07391046 |
Interventions
- Hospital-Based Vaccination Pathway (Biological)
Integration of vaccination counseling, prescription, and administration into hospital care pathways for vulnerable adult patients, including coordination with local public health vaccination services. No experimental vaccine is used; all vaccines are administered according to national guidelines.
Full eligibility criteria (from the record)
Inclusion Criteria: * Adults aged ≥18 years * Presence of at least one chronic or immunocompromising condition eligible for vaccination according to national guidelines * Written informed consent provided Exclusion Criteria: * Age <18 years * Conditions not included among the predefined eligibility criteria
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.